QRxPharma Pty Ltd.
This article was originally published in Start Up
QRx's lead (Phase II) candidate is a morphine/oxycodone combination that takes advantage of the synergistic effect of those two opioids when combined to produce a more potent painkiller, with fewer side effects, than morphine administered alone. The company is also developing an extended-release version of the drug and has a platform for discovering venom-based therapeutics.
You may also be interested in...
Start-ups venturing into the pain management arena will find them selves in a therapeutic category rich in both unmet medical need and competition. To compete, a number of newer companies are pursuing business models that balance the risks inherent in developing novel painkillers with more reliable, predictable routes to commercialization--such as creating next-generation versions of off-patent drugs and inlicensed technology, as well as establishing IP around already-elucidated targets.
Sanofi has deprioritized its presence in type 1 diabetes in recent years but could help turn teplizumab into a game-changer blockbuster product.
The European Medicines Agency has accepted Biogen’s marketing authorization submission for its BIIB800, developed by Chinese firm Bio-Thera.